CD38 in chronic lymphocytic leukemia: from bench to bedside?

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Human CD38 is a multifunctional cell surface protein.
• It acts as an enzyme producing Ca2+ metabolites (cADPR, ADPR) and as a receptor regulating lymphocyte signaling.
• CD38 is an independent negative prognostic factor in chronic lymphocytic leukemia (CLL).

Purpose of the Study:

• To investigate the functional role of CD38 in the neoplastic context of CLL.
• To elucidate the molecular mechanisms underlying CD38's prognostic significance in CLL.
• To explore CD38's potential as a therapeutic target in CLL.

Main Methods:

• Analysis of CD38's role within supramolecular complexes in CLL cells.
• Investigating the integration of proliferative and migratory signals mediated by CD38.
• Evaluating CD38's function as a disease marker and potential therapeutic target.

Main Results:

• CD38 is a central component of a large supramolecular complex in CLL.
• This complex includes signaling receptors, chemokine receptors, adhesion molecules, and matrix metalloproteases.
• CD38 enhances signal transduction, chemotaxis, and homing, integrating proliferative and migratory signals.

Conclusions:

• CD38 is a functional molecule in CLL, not just a prognostic marker.
• It acts as an integrator of key signals driving CLL cell behavior.
• CD38 represents a promising therapeutic target for future CLL treatment strategies.